1365252-55-6

Basic information

• Product Name: 7-(benzyl(methyl)amino)-1-butyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• CAS NO: 1365252-55-6
• Molecular Weight: 382.435
• Mol File: 1365252-55-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 7-(benzyl(methyl)amino)-1-butyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyl(methyl)amino)-1-butyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid(1365252-55-6)
• EPA Substance Registry System: 7-(benzyl(methyl)amino)-1-butyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid(1365252-55-6)

Safety Data

• Hazardous Substances Data: 1365252-55-6(Hazardous Substances Data)

Upstream product

• 70458-93-4 7-Chloro-6-fluoro-4-hydroxy-3-quinolinecarboxylic acid ethyl ester 
• 70032-30-3 diethyl 2-[(3-chloro-4-fluorophenylamino)methylene]malonate 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 1260740-31-5 ethyl 1-butyl-7-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 70032-24-5 1-butyl-7-chloro-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 103-67-3 benzyl-methyl-amine 

Downstream Products

• 1365252-70-5 N-benzyl-7-(benzyl(methyl)amino)-1-butyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant articles and documents

Synthesis and structure-activity relationships of new quinolone-type molecules against trypanosoma brucei

Human African trypanosomiasis (HAT) or sleeping sickness is caused by two subspecies of Trypanosoma brucei, Trypanosoma brucei gambiense, and Trypanosoma brucei rhodesiense and is one of Africa's old plagues. It causes a huge number of infections and cases of death per year because, apart from limited access to health services, only inefficient chemotherapy is available. Since it was reported that quinolones such as ciprofloxacin show antitrypanosomal activity, a novel quinolone-type library was synthesized and tested. The biological evaluation illustrated that 4-quinolones with a benzylamide function in position 3 and cyclic or acyclic amines in position 7 exhibit high antitrypanosomal activity. Structure-activity relationships (SAR) are established to identify essential structural elements. This analysis led to lead structure 29, which exhibits promising in vitro activity against T. b. brucei (IC50 = 47 nM) and T. b. rhodesiense (IC50 = 9 nM) combined with low cytotoxicity against macrophages J774.1. Screening for morphological changes of trypanosomes treated with compounds 19 and 29 suggested differences in the morphology of mitochondria of treated cells compared to those of untreated cells. Segregation of the kinetoplast is hampered in trypanosomes treated with these compounds; however, topoisomerase II is probably not the main drug target.